Med Life S.A.

BVB:M Lagerbericht

Marktkapitalisierung: RON 3.2b

Med Life Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Med Life wird ein jährliches Gewinn- und Umsatzwachstum von 92.9% bzw. 11.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 93.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 24.4% betragen.

Wichtige Informationen

92.9%

Wachstumsrate der Gewinne

93.7%

EPS-Wachstumsrate

Healthcare Gewinnwachstum24.3%
Wachstumsrate der Einnahmen11.5%
Zukünftige Eigenkapitalrendite24.4%
Analystenabdeckung

Low

Zuletzt aktualisiert27 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Med Life S.A. (BVB:M) Trading At A 41% Discount?

Aug 06
Is Med Life S.A. (BVB:M) Trading At A 41% Discount?

The Market Lifts Med Life S.A. (BVB:M) Shares 25% But It Can Do More

Jun 08
The Market Lifts Med Life S.A. (BVB:M) Shares 25% But It Can Do More

Is Med Life (BVB:M) A Risky Investment?

Apr 05
Is Med Life (BVB:M) A Risky Investment?

Returns On Capital Signal Tricky Times Ahead For Med Life (BVB:M)

Jul 05
Returns On Capital Signal Tricky Times Ahead For Med Life (BVB:M)

Is Med Life (BVB:M) A Risky Investment?

Jan 06
Is Med Life (BVB:M) A Risky Investment?

Med Life (BVB:M) Hasn't Managed To Accelerate Its Returns

Dec 06
Med Life (BVB:M) Hasn't Managed To Accelerate Its Returns

We Think Med Life (BVB:M) Is Taking Some Risk With Its Debt

Sep 27
We Think Med Life (BVB:M) Is Taking Some Risk With Its Debt

Returns Are Gaining Momentum At Med Life (BVB:M)

May 05
Returns Are Gaining Momentum At Med Life (BVB:M)

Is There An Opportunity With Med Life S.A.'s (BVB:M) 49% Undervaluation?

Mar 01
Is There An Opportunity With Med Life S.A.'s (BVB:M) 49% Undervaluation?

Med Life (BVB:M) Shareholders Will Want The ROCE Trajectory To Continue

Jan 22
Med Life (BVB:M) Shareholders Will Want The ROCE Trajectory To Continue

Does Med Life (BVB:M) Have A Healthy Balance Sheet?

Aug 31
Does Med Life (BVB:M) Have A Healthy Balance Sheet?

Med Life's (BVB:M) Returns On Capital Are Heading Higher

Jun 10
Med Life's (BVB:M) Returns On Capital Are Heading Higher

Here's Why We Think Med Life (BVB:M) Is Well Worth Watching

May 26
Here's Why We Think Med Life (BVB:M) Is Well Worth Watching

Is Now An Opportune Moment To Examine Med Life S.A. (BVB:M)?

May 12
Is Now An Opportune Moment To Examine Med Life S.A. (BVB:M)?

Is There An Opportunity With Med Life S.A.'s (BVB:M) 24% Undervaluation?

Apr 12
Is There An Opportunity With Med Life S.A.'s (BVB:M) 24% Undervaluation?

Update: Med Life (BVB:M) Stock Gained 98% In The Last Year

Mar 16
Update: Med Life (BVB:M) Stock Gained 98% In The Last Year

Should We Be Excited About The Trends Of Returns At Med Life (BVB:M)?

Mar 04
Should We Be Excited About The Trends Of Returns At Med Life (BVB:M)?

Should You Be Impressed By Med Life S.A.'s (BVB:M) ROE?

Feb 20
Should You Be Impressed By Med Life S.A.'s (BVB:M) ROE?

Med Life (BVB:M) Seems To Use Debt Quite Sensibly

Feb 07
Med Life (BVB:M) Seems To Use Debt Quite Sensibly

Is It Too Late To Consider Buying Med Life S.A. (BVB:M)?

Jan 25
Is It Too Late To Consider Buying Med Life S.A. (BVB:M)?

Do Med Life's (BVB:M) Earnings Warrant Your Attention?

Jan 08
Do Med Life's (BVB:M) Earnings Warrant Your Attention?

Is Med Life S.A. (BVB:M) Trading At A 22% Discount?

Dec 23
Is Med Life S.A. (BVB:M) Trading At A 22% Discount?

Did You Miss Med Life's (BVB:M) 49% Share Price Gain?

Dec 08
Did You Miss Med Life's (BVB:M) 49% Share Price Gain?

The Trends At Med Life (BVB:M) That You Should Know About

Nov 24
The Trends At Med Life (BVB:M) That You Should Know About

Gewinn- und Umsatzwachstumsprognosen

BVB:M - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (RON Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20263,301187442N/A1
12/31/20252,94789314N/A1
12/31/20242,62624N/AN/A1
9/30/20242,5662210272N/A
6/30/20242,4611826274N/A
3/31/20242,33711-15223N/A
12/31/20232,2224-36184N/A
9/30/20232,116-1140268N/A
6/30/20232,020-3-10179N/A
3/31/20231,9211223212N/A
12/31/20221,8103215185N/A
9/30/20221,7256410112N/A
6/30/20221,6238083202N/A
3/31/20221,52098122209N/A
1/1/20221,438103130227N/A
9/30/20211,359107103185N/A
6/30/20211,29511267172N/A
3/31/20211,1608347148N/A
1/1/20211,0875740129N/A
9/30/20201,0333649145N/A
6/30/20209741677134N/A
3/31/20201,0071863113N/A
12/31/20199751454107N/A
9/30/2019939203276N/A
6/30/2019902162871N/A
3/31/201986111N/AN/AN/A
1/1/201980413-152N/A
9/30/20187458047N/A
6/30/20186995N/A41N/A
3/31/20186575N/AN/AN/A
1/1/20186284N/A36N/A
9/30/20176103N/A42N/A
6/30/2017577-2N/A39N/A
3/31/2017539-6N/AN/AN/A
1/1/2017508-5N/A43N/A
9/30/2016469-1N/A39N/A
12/31/20153969N/A42N/A
12/31/20143377N/A36N/A
12/31/2013306-4N/A23N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MDas prognostizierte Gewinnwachstum (92.9% pro Jahr) liegt über der Sparquote (6.3%).

Ertrag vs. Markt: MDie Erträge des Unternehmens (92.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt RO (-0.3% pro Jahr).

Hohe Wachstumserträge: MEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: MDie Einnahmen des Unternehmens (11.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt RO (1.5% pro Jahr).

Hohe Wachstumseinnahmen: MDie Einnahmen des Unternehmens (11.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (24.4%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y